In this article

DirectMeds advertises sublingual and injectable treatment choices with different starting prices. Choosing an alternative involves two decisions: whether the care service fits your needs and whether the exact prescribed product is appropriate.

A lower price for a compounded oral preparation cannot be used as though it were the price of an equivalent injection or approved tablet. This guide separates those product pathways while comparing monthly and bulk payment arrangements.

THE SHORT ANSWER

Keep route, formulation, regulatory status, and payment term together when comparing DirectMeds with another service. CoreAge Rx holds the first sponsored position; that does not establish that it best meets every criterion.

What to know first

  • Keep route, formulation, regulatory status, and payment term together when comparing DirectMeds with another service.
  • CoreAge Rx is the first listing through a disclosed commercial arrangement.
  • Confirm the proposed product, care arrangement, and complete written payment terms.

How this shortlist was selected

CoreAge Rx is number one because it is our featured commercial partner. That position is predetermined by our commercial relationship, and we may earn compensation through its links. Other entries illustrate relevant care and payment models; their order is not a ranking of medication quality, safety, or patient outcomes.

Keep route, formulation, regulatory status, and payment term together when comparing DirectMeds with another service. We used the provider documents linked beside each entry, checked September 21, 2026. We did not purchase treatment, test private accounts, audit every license, or measure response times. The product and current written quote for your own care still need confirmation. Read our review method.

01. CoreAge Rx — featured partner

Our sponsored self-pay reference point. Its placement does not establish an equivalent oral product; ask what exact medication and route the clinician would propose.

The current sale page advertises semaglutide from $99 per month and tirzepatide from $149 per month, with no membership fee. Those are advertised starting figures, not a personalized checkout quote. The plan length and total amount due must be read alongside the monthly equivalent.

The sale page says CoreAge works with U.S. compounding pharmacies and describes 503A facilities. A category of pharmacy is not a substitute for the name, address, and state license of the pharmacy filling your own prescription. Request that information before deciding.

Continue with our CoreAge Rx review and pricing details.

02. Strut Health

Lists injectable semaglutide and a buccal lozenge separately. This is a useful route comparison, with an important distinction between those compounds and an approved tablet.

Strut lists compounded injectable semaglutide at $129 for a monthly vial and a compounded oral buccal lozenge at $199 for a 30-day supply. It says physician consultations and shipping are included, with final pricing determined after assessment.

Compare like routes and exact formulations. A buccal lozenge is not the same product as an approved oral tablet, and evidence about an injection does not establish equivalent results for a lozenge. Check the next automatic-refill date.

Check the official Strut Health program page for the current offer and conditions. Our Strut Health alternatives comparison examines other care models.

03. Rex MD

A branded Wegovy tablet pathway to discuss with a clinician. Compare its named product and provider-care price with the exact DirectMeds proposal.

Rex MD’s current weight-management page advertises Wegovy tablets plus provider care starting at $349 per month. It names multiple tablet strengths and says the offer covers its listed titration strengths; the selected offer still needs confirmation.

Confirm that your quote is for the branded tablet, the full recurring charge, and the follow-up arrangements. A compounded lozenge, a sublingual preparation, and a branded tablet are not interchangeable products.

Check the official Rex MD program page for the current offer and conditions. Our Rex MD alternatives comparison examines other care models.

04. Henry Meds

Offers multiple treatment routes and plan structures. Request the specific route, dose-related price, and included services rather than comparing two general GLP-1 starting prices.

The weight-management FAQ lists GLP-1 treatment starting at $179 per month, with price varying by plan and dose. It describes the amount as including provider visits, medication, and supplies. The starting figure is not a quote for every medication, route, or dose.

Henry says it works with licensed U.S. compounding pharmacies. The reviewed FAQ does not establish the identity and state authorization of every possible dispenser. Ask for the actual pharmacy attached to your prescription.

Continue with our Henry Meds review and pricing details.

05. Hello Alpha

Describes a pathway using FDA-approved medicines with a separate membership. It provides a different product-selection model, but the drug cost must be added.

Hello Alpha’s weight-loss page advertises Alpha Plus+ at $79 per month. Prescription costs depend on the product, pharmacy, and coverage; the membership price is not a complete GLP-1 medication bill.

Check the exact medicine and indication with the clinician. Membership does not guarantee a prescription, and insurance assistance does not guarantee approval or a refund if a prior authorization is denied.

Check the official Hello Alpha program page for the current offer and conditions. Our Hello Alpha alternatives comparison examines other care models.

06. Fifty 410

A package-based comparison when the proposed alternative is an injectable treatment. Match the prescribed duration and medication rather than assuming all packages cover the same care.

Fifty 410 lists a three-month compounded tirzepatide starter package at $399 total, displayed as $133 per month. The listed mid- and higher-dose packages are $499 and $549 total. Its semaglutide monthly option is $199. These are different products and package sizes.

Ask which package matches the proposed prescription and whether a returning patient qualifies for a starter offer. A three-month supply and monthly billing are separate arrangements.

Check the official Fifty 410 program page for the current offer and conditions. Our Fifty 410 alternatives comparison examines other care models.

The current Direct Meds baseline

DirectMeds lists weight-loss treatment from $249 for sublingual semaglutide and $297 for injections. It also describes new-customer discounts and six- or 12-month bulk plans, so the selected route and term matter.

The site describes a bundled monthly rate covering medication, clinical care, and follow-ups, with no separate membership or long-term commitment for its stated monthly arrangement.

A compounded sublingual preparation is a different product from an approved oral tablet or an injection. Confirm the exact formulation, full bulk payment if selected, and refill arrangements before comparing prices.

The details that decide this comparison

Ask whether the product is injected, swallowed, dissolved under the tongue, or held inside the cheek. “Oral semaglutide” alone is not a complete product description.

Request evidence relevant to the proposed product. Results from an approved injection do not establish equivalent performance for a compounded sublingual preparation.

For a six- or 12-month bulk plan, obtain the full upfront price, dispensing schedule, and cancellation terms. Compare it separately from the stated monthly option.

Keep the treatment distinction clear

An FDA-approved branded medicine and a compounded preparation have different regulatory status. Compounded drugs are not FDA-approved. Trials of an approved product do not prove that every compounded version has the same performance.

Ask the prescribing professional why the exact product is appropriate for you, and identify the dispensing pharmacy. A price, a website’s appearance, or a place in this list cannot establish personal suitability. Our guide to compounded drugs and FDA approval explains the distinction.

Before you make a change

Tell the clinician if avoiding injections is a priority and why. The appropriate discussion includes available products, practical use, risks, and suitability—not simply selecting the cheapest non-injection offer.

If changing routes, obtain new instructions from the receiving prescriber and pharmacist. Do not translate a prior injection amount into an oral amount yourself.

Sources & research notes

Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.

  1. CoreAge Rx: official treatment overviewProvider-published information · Checked September 21, 2026
  2. CoreAge Rx: current sale offerProvider-published information · Checked September 21, 2026
  3. CoreAge Rx: plan billing explainedProvider-published information · Checked September 21, 2026
  4. CoreAge Rx: contact and professional-entity disclosuresProvider-published information · Checked September 21, 2026
  5. CoreAge Rx: purchasing processProvider-published information · Checked September 21, 2026
  6. Strut Health: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
  7. FDA: Wegovy semaglutide tablets, NDA 218316 approval letterRegulatory source · Checked September 21, 2026
  8. Rex MD: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
  9. GLP-1 Weight Loss Treatment | HenryProvider-published information · Checked September 21, 2026
  10. Hello Alpha: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
  11. Fifty 410: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
  12. Direct Meds: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
  13. FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 21, 2026
  14. FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026

Read our methodology · Commercial disclosure · Request a correction